A Feasibility Study of Postoperative Adjuvant Therapy of Carboplatin and Weekly Paclitaxel for Completely Resected Non-small Cell Lung Cancer

IntroductionRecent clinical trials have shown significant survival benefits from postoperative adjuvant therapy for respectable nonsmall cell lung cancer (NSCLC). However, evaluation of adjuvant chemotherapy with carboplatin combination is still uncertain. The purpose of the study was to test the feasibility of adjuvant chemotherapy with carboplatin and separate weekly paclitaxel after complete resection of pStage IB, II, IIIA NSCLC in a multicenter study.MethodsThe study was conducted from 2001 to 2006 in the outpatient setting. A total of 61 patients were enrolled. Patients received adjuvant chemotherapy with 4 cycles of carboplatin (AUC 5) on day 1 and paclitaxel (70 mg/m2) on day 1, 8, and 15 every 4 weeks. Primary endpoints were toxicity and chemotherapy compliance. Secondary endpoints were disease-free survival and overall survival.ResultsMore than 65% of eligible patients had pStage IIIA. The median number of chemotherapy cycles was 4 (range 1–4). Grade 3 or 4 toxicities of neutropenia were 34% (grade 4: 2%). Other hematologic adverse effects were extremely less frequent. Regarding the nonhematologic adverse effect, hair loss was frequent; however, peripheral neuralgia was less frequent. Treatment-related death was not registered. During median follow-up of 21 months, 24 patients developed recurrent disease. Estimated disease-free survival and overall survival at 2 years was 51.2% and 84.6%, respectively.ConclusionsPostoperative carboplatin and weekly paclitaxel showed favorable feasibility and acceptable toxicity in comparison with the cisplatin-containing regimen. Consequently, it is desirable that this regimen would be validated in a phase III clinical trial for NSCLC after curative resection

DIC を合併した急性膵炎患者血漿中の低分子ウロキナーゼ

It was confirmed by zymographic technique that 1 ml of normal human plasma possessed about 0.2 IU of urokinase activity which is a high molecular weight form with a molecular weight of 53,000. Plasma of an acute pancreatitis patient followed by disseminated intravascular coagulation possessed the same amount of urokinase activity as normal plasma, and was confirmed to be composed of two types of urokinase, a high molecular weight form and a low molecular weight form with a molecular weight of 33,000

気腫性巨大肺嚢胞に合併した原発性肺癌の検討

Operations for emphysematous giant bulla have been performed on 17 patients. Complications of primary lung cancer were observed in four of the 17 patients. All the patients who had such lung cancer were male and heavy smokers. As to histological type, squamous cell carcinoma were found in three patients and undifferentiated cancer of large cell type in one patient. The three had squamous cell carcinoma generated from the bronchus on the central side of the giant bulla, while the large cell carcinoma observed in one patient was generated from the bronchus close to the bulla. In two patients, cancer was generated while bulla was under observation. In one patient, the generation of cancer was found simultaneously with the bulla discovery. In the other patient, cancer was generated after bullectomy. These findings suggest that physicians should always pay careful attention to generation and complication of cancer while treating giant bull

凝固因子 X とプラスミンの相互作用に関する研究

Coagulation factor X was isolated from normal human plasma by a two-step sequential affinity column chromatography method. The concentration of factor X was confirmed to be 115 units per litter of plasma. In the present study, it was first confirmed that factor X could be activated to factor Xa by Lys-plasmin

ゼロマンモグラー : 59例の乳癌および204例の非癌性乳腺疾患の検討

Of female patients who were subjected to mammary gland xeromammography at the 2nd Dept. of Surgery, Hiroshima University School of Medicine for a period from 1979 to 1983, 59 patients with palpable breast cancer and 204 non-cancerous patients confirmed pathologically were studied mainly in regard to direct signs. The incidence of cancer was relatively high in P2 and DY (so-called high-risk) parenchymal pattern groups, indicating necessity of minute interpretation of mammograms in these two groups. As for direct signs of breast cancer, the incidence of tumor shadow was 77.9% (46/59) and that of calcification including microcalcification (21 cases) was 42.9% (25/59) in cancer patients. The false negative rate of xerommography was 13.6% (8/59), attributable to misinterpretation in 4 cases and to mammograms themselves which were completely normal in the remaining 4 cases. The mean age of the false negative cases seemed to be younger than that of whole cancer cases (59 cases) while neither histopathological findings nor parenchymal patterns significantly correlated with the results

ヒト乳癌におけるエストロゲン依存性の検討 : Ⅱ. 進行又は再発乳癌に対するタモキシフェンの臨床的評価

An antiestrogen (tamoxifen) was given to 17 patients with advanced breast cancer (both recurrent and primary cancers) during a period from June 1981 to September 1983. The response rate to the antiestrogen was 47.8% (8/17). Sixty percent (6/10) of patients with estrogen receptor positive (ER +) responded, compared with 16.7% (1/6) of patients with estrogen receptor negative (ER －). Forty percent of patients with soft tissue/lymph nodes involvement responded, compared with 27.2% in patients with bone metastasis, and 25.0% in patients with visceral involvement. Postmenopausal patients responded more than premenopausal ones. In recurrent cases, the response rate increased with the prolongation of disease free interval. Eight out of 17 patients are still alive, and the longest survival case has been in a condition of partial response for 23 months so far. The mean survival period in 9 deaths was 13±9 months, with longest 32 months. As shown here, some patients with advanced breast cancer respond very well to the therapy. From these results, we think the tamoxifen-containing endocrinotherapy in combination with chemotherapy is effective in treatment of · advanced cancer and its active application may enable patients to live longer in the rehabilitated situation

胸腺原発カルチノイドの経験

This paper reports two relatively rare cases of primary carcinoid tumors of the thymus experienced by the authors. One case is a 43-year old male who presented the Zollinger-Ellison (ZE) syndrome and received total gastrectomy and distal pancreatectomy. Mediastinal tumor was found one year and seven months post operatively, for which total extirpation was performed followed by irradiation. The histological diagnosis was primary carcinoid of the thymus. The other case is a 63-year old female, who under the diagnosis of thymus carcinoid received total removal of the tumor with postoperative irradiation in 1978. In 1984, the case developed localized recurrence of the tumor, for which excision was performed again and irradiation was repeated

ヒト乳癌におけるエストローゲン依存性の検討 : I. ヒト乳癌組織におけるエストローゲンレセプターの細胞化学的研究

We have had an opportunity to determine estrogen receptor (ER) in cytoplasmic fractions of primary breast cancer specimens taken from 79 patients under a fluorescent microscope using fluorescent estradiol conjugate as a tracer. In this study, an estrogen receptor is reported as positive when not less than 10% of carcinoma cells incorporate fluorescent estradiol conjugate into cytoplasma. The ER positive rate was 61% in the total cases, varying by age: 70% in 40s and younger, 43% in 50s, and 60% in 60s and older patients. Sixty-eight % of premenopausal breast cancers conpared to 54% of postmenopausal ones were ER positive. Broken down by the histological type, the rates were 70% in papilla-tubular carinoma, 59 % in medullary tubular carcinoma, and 57 % in scirrhous type. The rates by tumor size according to the clinical TNM classification were 70 % in T1, 59% in T2, 91% in T3, and 34% in T4. The rates by stage difined by the pathological TNM classification were 65 % in Stage I, 50% in Stage II, 87% in Stage III, and 45% in Stage IV. We discuss our findings and review others, as well